Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| YA0510KR | Other Identifier | company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EE30/DRSP (Yasmin, BAY86-5131) | Drug | Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and efficacy in real practice | After 6 cycle of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Demography | At initial visit | |
| Medical History | At initial visit | |
| Administration period of Yasmin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Korean women who need oral contraceptive
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | South Korea |
Not provided
| ID | Term |
|---|---|
| C534342 | drospirenone and ethinyl estradiol combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| After 6 cycle of treatment or at the point of withdrawan |
| Patient's compliance | After 6 cycle of treatment or at the point of withdrawan |
| Adverse Event / Serious AE collection | At point of the occurence |